Assessments of outcome in haemophilia - a patient perspective

Haemophilia

Volumn 22, Issue 3, 2016, Pages e208-e209

  O'Mahony, B ^a,b   Skinner, M W ^c   Noone, D ^a   Page, D ^d   O'Hara, J ^e  

^a IRISH HAEMOPHILIA SOCIETY   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Institute for Policy Studied   (United States)

^d Canadian Hemophilia Society   (Canada)

^e The Innovation Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; CLINICAL DECISION MAKING; COST UTILITY ANALYSIS; DAILY LIFE ACTIVITY; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEMOPHILIA; HUMAN; LETTER; MEDICATION COMPLIANCE; MUSCULOSKELETAL FUNCTION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC FIGURE; QUALITY OF LIFE ASSESSMENT; RESOURCE ALLOCATION; SELF REPORT; HEMOPHILIA A; QUALITY OF LIFE;

BLOOD CLOTTING FACTOR 9;

FACTOR IX; HEMOPHILIA A; HUMANS; QUALITY OF LIFE;

EID: 84960864158     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12922     Document Type: Letter

References (15)

1. van den Berg HM, Feldman BM, Fischer K, Blanchette V, Poonnoose P, Srivastava A. Assessments of outcome in haemophilia - what is the added value of QoL tools? Haemophilia 2015; 21: 430-5.
2. International Classification of Functioning, Disability and Health, World Health Organisation. Available at http://www.who.int/classifications/icf/en/. Accessed January 7, 2016.
3. Noone D, O'Mahony B, van Dijk JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013; 19: 44-50.
4. Noone D, O'Mahony B, Prihodova L. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries. Haemophilia 2011; 17: e842-3.
5. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia 2013; 19: e239-47.
6. O'Mahony B, Noone D, Giangrande PLF, Prihodova L. Haemophilia care in Europe: a survey of 19 countries. Haemophilia 2011; 17: 35-40.
7. Page D. Patient perspective - attitudes, expectations and desires for new and emerging therapies. Abstracts. Haemophilia 2014; 20: 179.
8. Farrugia A, Cassar J, Kimber M et al. Treatment for life for severe haemophilia A - a cost utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013; 19: e228-38. doi: 10.1111/hae.12121.
9. Giangrande P, Seitz R, Behr-Gross ME et al. Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia 2014; 20: 322-5.
10. Resolution CM/res 92015)3 on principles concerning haemophilia therapies (Adopted by the Committee of Ministers on 15 April 2015 at the 1225th meeting of the Ministers Deputies). Available at https://wcd.coe.int/ViewDoc.jsp?id&2311001%26Site=CM. Accessed July 8, 2015.
11. Krishnan S, Vietri J, Furlan R, Duncan N. Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey. Haemophilia 2015; 21: 64-70.
12. Khair K. Compliance, concordance and adherence: what are we talking about? Haemophilia 2014; 20: 601-3.
13. Nugent D, Kalnins W, Querol F et al. Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population. Haemophilia 2015; 21: e26-38.
14. Patient Reported Outcomes Burdens and Experiences (PROBE) Study. ClinicalTrials.gov Identifier: NCT02439710.
15. Cost of Haemophilia across Europe" A Socioeconomic Survey (CHESS). Available at http://www.haemophilia.org.uk/bleeding_disorders/research/the_burden_of_haemophilia. Accessed July 1, 2015.